Endocrinol Metab.  2022 Feb;37(1):62-64. 10.3803/EnM.2022.1403.

Drug Repositioning: Exploring New Indications for Existing Drug-Disease Relationships

• Kim HS

• KMID: 2527137
• DOI: http://doi.org/10.3803/EnM.2022.1403

Figure

• 

  Fig. 1 Comparison between (A) traditional drug development and (B) drug repositioning. Modified from Xue et al. [7]. FDA, U.S. Food and Drug Administration.

Reference

1. Becker RC. Covid-19 treatment update: follow the scientific evidence. J Thromb Thrombolysis. 2020; 50:43–53.

2. Jarada TN, Rokne JG, Alhajj R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. J Cheminform. 2020; 12:46.

3. Yeu Y, Yoon Y, Park S. Protein localization vector propagation: a method for improving the accuracy of drug repositioning. Mol Biosyst. 2015; 11:2096–102.

4. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009; 8:959–68.

5. Saberian N, Peyvandipour A, Donato M, Ansari S, Draghici S. A new computational drug repurposing method using established disease-drug pair knowledge. Bioinformatics. 2019; 35:3672–8.

6. Low ZY, Farouk IA, Lal SK. Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses. 2020; 12:1058.

7. Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018; 14:1232–44.

8. U.S. Food and Drug Administration. Drug development & approval process [Internet]. Silver Spring: FDA;2019. [cited 2022 Feb 3]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs .

9. Nosengo N. Can you teach old drugs new tricks? Nature. 2016; 534:314–6.

10. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012; 11:191–200.

11. Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacotherapy. 2015; 35:926–34.

12. Lotfi Shahreza M, Ghadiri N, Mousavi SR, Varshosaz J, Green JR. A review of network-based approaches to drug repositioning. Brief Bioinform. 2018; 19:878–92.

13. Park N, Jeon JY, Jeong E, Kim S, Yoon D. Drug repositioning using temporal trajectories of accompanying comorbidities in diabetes mellitus. Endocrinol Metab (Seoul). 2022; 37:65–73.

14. Kim HS, Kim JH. Proceed with caution when using real world data and real world evidence. J Korean Med Sci. 2019; 34:e28.

15. Kim HS, Kim DJ, Yoon KH. Medical big data is not yet available: why we need realism rather than exaggeration. Endocrinol Metab (Seoul). 2019; 34:349–54.

16. Lee S, Kim HS. Prospect of artificial intelligence based on electronic medical record. J Lipid Atheroscler. 2021; 10:282–90.

17. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014; 36:e2014008.

18. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43:69–77.

19. Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. J Lipid Atheroscler. 2021. Nov. 26. [Epub]. https://e-jla.org/DOIx.php?id=10.12997/jla.2022.11.e1 .

20. Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018; 33:e213.